IMPORTANCE Although brief intervention is effective for reducing problem alcohol use, few data exist on its effectiveness for reducing problem drug use, a common issue in disadvantaged populations seeking care in safety-net medical settings (hospitals and community health clinics serving low-income patients with limited or no insurance).
grams of screening, brief intervention, and referral to treatment (SBIRT) for "alcohol and drugs" have been implemented on a widespread scale. 3, 4 This rapid adoption of brief intervention for drugs other than alcohol has outstripped its meager evidence base. Of the 3 randomized clinical trials of brief intervention for drug abuse in non-treatment-seeking individuals, 5-8 only 2 were positive, 7, 8 and only 1 found an effect among US patients. 8 Ambulatory primary care is an important setting to test the effectiveness of brief intervention because of the large volume of patients seen in that setting. 9 The majority of patients with problem drug use in this setting are not accessing substance abuse treatment. 4, 10 Adding brief substance abuse interventions onsite in primary care is also consistent with newly emerging "integrated care" models. 11 Recent studies show that a disproportionate number of individuals with drug abuse or dependence are from lower socioeconomic strata 12 and primarily receive care in public sector hospitals and community health clinics (ie, safety-net medical settings that serve low-income patients with limited or no insurance). Although the cost of untreated drug abuse in this system is substantial (eg, mortality, crime, lost productivity, increased medical care), 13 there is limited information on these public health-relevant outcomes for brief intervention. 14, 15 Policy makers need such data to create traction to drive policy changes required to improve substance abuse treatment. The purpose of this study was to determine whether a brief intervention using motivational interviewing would reduce problem drug use in safety-net primary care patients and increase admission to specialist substance abuse treatment. We also sought to estimate the effects of the brief intervention on several public health outcomes directly related to problem drug use.
Methods

Design
A 2-group randomized clinical trial was conducted to examine the effects of a 1-time brief intervention using motivational interviewing with attempted telephone booster compared with enhanced care as usual. A hybrid efficacyeffectiveness design was chosen to enhance external validity by using a brief intervention protocol similar to that used in the Substance Abuse and Mental Health Services Administration-funded Washington State SBIRT study 16 and having the intervention delivered by social workers already working with patients in these clinics. 17 The study was approved by an institutional review board and an independent data and safety monitoring board. Further details about study design and rationale have been described. 18 
Participants
Participants were recruited between April 2009 and September 2012 from the waiting rooms of 7 safety-net (public hospitalassociated) primary care clinics in King County, Washington. Inclusion criteria were age 18 years or older; self-reported use of an illegal drug or nonprescribed medication (ie, problem drug use) at least once in the 90 days before screening 19 ; English-speaking and able to read and understand screening and consent forms (sixth-grade literacy); currently receiving and planning to continue receiving care in the clinic; and having telephone or e-mail access to facilitate scheduling follow-up assessments. Exclusion criteria were attendance in formal substance abuse treatment in the past month (excluding selfhelp groups such as Narcotics Anonymous); high risk of imminent suicide; life-threatening medical illness; severe cognitive impairment; or active psychosis. All participants provided written informed consent and received compensation in gift cards for completion of study assessments ($25 at baseline and 3 months, $30 at 6 months, $35 at 9 months, $40 at 12 months, and $10 for urine samples at each follow-up).
Randomization
After a brief baseline assessment, participants were randomized in a 1:1 ratio ( Figure) to brief intervention or enhanced care as usual using permuted blocks stratified by clinic and by 3 factors known to affect outcome: drug use severity 20 (goal of abstinence on Thoughts about Abstinence assessment). Varying-sized blocks were generated prior to enrollment, and allocation was concealed in sequentially numbered opaque envelopes opened by the research assistant at randomization.
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Intervention
To maximize the possibility of an effect while maintaining realworld feasibility, brief interventionists were recruited from social workers in participating clinics (n = 11). 24 The interventionists agreed to adhere to the study protocol, including ongoing training and supervision, and to provide written informed consent (because data on their fidelity to the motivational interviewing model would be used for the study). Additional master's-and bachelor's-level interventionists not working in the clinics (n = 6) were later added to help meet recruitment goals. All interventionists were trained by 1 of the original trainers for the Substance Abuse and Mental Health Services Administration's national SBIRT initiative 3 using a group workshop followed by individual feedback on audiotaped role-plays with up to 5 standardized patients over the course of 5 weeks. 25 All interventionists met basic motivational interviewing proficiency training goals on at least 1 practice role-play.
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Participants randomized to the intervention condition were to receive a single, approximately 30-minute brief intervention. The clinical tasks of the intervention protocol were to give participants feedback about their drug use screening (DAST-10) results, explore the pros and cons of drug use, increase par-ticipant confidence in being able to change, and discuss options for change. When appropriate, interventionists used an illustrated handout depicting the participant's DAST-10 score and its associated problem severity (low, intermediate, substantial/severe) to aid the discussion (the DAST-10 feedback handout is available in the eAppendix in the Supplement) and provided a list of substance abuse treatment resources. A motivational interviewing approach was used to perform these tasks, with the hope that understanding and exploring ambivalence about change among vulnerable, underserved participants while eliciting their own arguments for change might empower them and bridge cultural differences. Also, as opposed to a "one size fits all" intervention, this tailored approach allowed flexibility as to which or how many drugs to target, as well as in how to guide the participant (eg, specialty treatment, abstinence, harm reduction). The same interventionist attempted a follow-up telephone booster session within 2 weeks of the intervention. Interventions were audio recorded and scored by trained coders using the Motivational Interviewing Treatment Integrity (MITI) coding system.
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Monthly group supervision and ongoing e-mailed feedback from the trainer (25% of recorded brief interventions) were used to maintain intervention fidelity. To maximize external validity, MITI scoring feedback was not given to interventionists for training role-plays or for real-patient supervision.
Enhanced Care as Usual
Participants in the enhanced care as usual group received the same illustrated handout depicting their DAST-10 drug problem severity score and list of substance abuse treatment resources. These were provided with only a quick introduction by the research assistant to minimize intervention elements in the control condition and resembled the "notification and referral" strategy that might be implemented in high-quality usual care.
Assessment Measures
The assessment battery, administered by trained research assistants, was brief to minimize any unintended intervention effects 17, 28 and to maximize the chance of completing study procedures around a primary care visit. The baseline interview assessed demographics, including self-reported race and ethnicity; substance abuse severity (DAST-10) 20 ; drug use in the previous month, comorbid medical and mental illness, and social and legal outcomes related to drug use (ASI) 29 ; goal for changing drug use (Thoughts about Abstinence assessment)
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; and the HIV Risk-taking Behavior Scale. 30 Urine samples for drug screens were also collected to track point prevalence of actual drug use. All measures except the demographics and DAST-10 were repeated at 3-, 6-, 9-, and 12-month follow-up assessments conducted by research assistants blinded to randomization assignment. The last 12-month assessment was completed on September 20, 2013.
Primary Outcomes
The primary outcome, prespecified on ClinicalTrials.gov, was self-reported days of drug use during the past 30 days. The ASI measures drug use for individual drugs but does not include an omnibus category for number of days with any drug use. As a proxy for this, present analyses focused on the most frequently used drug at baseline for each individual. This was supplemented with the ASI Drug Use composite score (range, 0-1; 1 indicates greatest severity), an integrated measure of frequency of use and associated problems for all drugs used. For both primary outcomes, measurement of drug use excluded use of alcohol and prescription drugs when used as prescribed.
Secondary Outcomes
Medical, psychiatric, social, and legal subscales of the ASI were used to assess functional correlates of drug use. The assessments were supplemented with Washington State administrative data, which included chemical dependency treatment records, inpatient hospitalizations, state patrol arrest records, and death records. Emergency department and outpatient visits were also tracked using electronic medical record data from the safety-net medical center where the study took place.
Analysis
Acute treatment differences in primary outcomes (days used during last 30 days and drug use composite) focused on preintervention to 3 months postintervention and used a difference in differences analysis strategy. 31 Long-term treatment differences during 12 months postintervention were analyzed using generalized estimating equations (GEEs). 32 Because days of use was highly bimodal, the original count variable was divided into 4 categories of days of use (0, 1-10, 11-20, 21-30) and analyzed using an ordinal GEE, 33 whereas the drug use composite score was analyzed with a gaussian GEE. For both outcomes, alternative distributions (eg, negative binomial, log-normal) were examined, but all substantive conclusions were identical to those reported. Covariates included baseline value of the outcome, indicator variables for the clinics where recruitment occurred, and baseline values of the stratification variables used in randomization. Administrative data were analyzed via logistic regression, and ASI scores for medical, psychiatric, social, and legal domains were analyzed via linear regression. Prespecified treatment effect modification of primary outcomes was examined for baseline stratification variables of drug use severity, comorbid psychiatric illness, and motivation to change drug use. As a post hoc exploratory analysis, treatment effect modification of select secondary outcomes was also examined. All analyses were intention-to-treat, with all available data from participants analyzed by randomization group. There were few missing data overall (87% of planned assessments completed), and GEE analyses made use of all available data. Significance was based on 2-sided P values <.05. A priori power analyses concluded that a trial with an initial sample of 1000 with 25% attrition (ie, 375 participants per group) yielded 80% power to detect small treatment differences in drug use (defined by 2.5% reduction in drug use frequency). All analyses were conducted using either SPSS version 19.0 (IBM Corp), Stata version 13 (StataCorp), or R version 3.0.2.
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Of 1621 eligible participants, 868 (54%) were randomized ( Figure 1) . Follow-up rates were greater than 87% at all 4 points (3, 6, 9, and 12 months) and were similar in both groups. Participants without follow-ups (n = 45) were not significantly different from participants with follow-ups (n = 823) on baseline measures or by randomization group. Assessments averaged 25 minutes, and the majority of assessments were conducted in person (91%).
At baseline, the sample composition was similar in both groups: middle aged, mostly men (70%), nonwhite (55%), single (81%), and not working (91%); approximately 30% were homeless at least 1 night in the past 90 days ( Table 1) . In the year prior to enrollment, participants had substantial medical comorbidity (mean, >6 medical conditions), 35 with notable percentages of hospitalization (25%) and emergency department use (49%); 10% had received chemical dependency treatment ( Table 2) . Drug use was similar between groups (mean, 13.82 [SD, 11.00] days of the most frequently used drug) and was highly heterogeneous, with different types and patterns of use evident according to the severity of drug use measured by validated DAST-10 score categories (eTable 1 and eTable 2 in the Supplement). Many participants also used alcohol, but because we had no data on quantity of alcohol consumed per drinking day, determining degree of hazardous alcohol use was not possible. Supplementing self-reported drug use with positive urine screen results only slightly increased the proportion of individuals classified as using particular drugs (eTable 3 in the Supplement). A majority of participants (56%) had some comorbid mental illness, and a minority (37%) had the goal to try to abstain from drugs. These 2 stratification variables were also significantly associated with problem drug use severity such that the most severe group was most likely to have a goal of abstinence and also to have more mental illness.
Intervention Participation and Fidelity
Of the 435 participants randomized to the intervention, 423 (97%) received a brief intervention and 203 (47%) received a booster call. Most participants (90%) received the brief intervention on the same day as the baseline assessment, but for logistical reasons, the remaining 10% had to return to the clinic for the intervention a median of 4 days after assessment. The brief intervention averaged 27 minutes, and 86% of interventions were recorded. Mean interventionist scores for all audiorecorded brief interventions met basic proficiency cutoffs for 4 of 5 MITI summary scores, suggesting adequate but not expert proficiency. 26 Over the course of the next year, a small number of participants in both conditions (brief intervention: n = 26; enhanced care as usual: n = 34) received brief interventions outside the study via regular clinical services. Table 2 reports the secondary outcome variables, including ASI scores for medical, psychiatric, employment, social, and legal domains, proportion of individuals who accepted a referral to chemical dependency treatment and had an initial treatment contact, and relevant public health outcomes (eg, medical care use, arrests, deaths). There were no significant intervention effects on any secondary outcomes, including admission to chemical dependency treatment.
Main Outcomes
Effect modification of primary drug use outcomes by baseline drug use severity, psychiatric comorbidity, and motivation to change revealed no significant moderation effects (eTable 4 and eTable 5 in the Supplement). However, in exploratory effect modification analyses of secondary outcomes, drug use severity significantly moderated intervention effects on both admission to treatment and emergency department use. Participants with high drug problem severity receiving the intervention were more likely to enter specialist drug treatment and more likely to reduce their use of the emergency department ( Table 3 and eTable 6 in the Supplement).
Discussion
In the overall sample, participants who received a brief intervention using proficiency-level motivational interviewing showed no benefit across multiple domains, including drug use frequency, admissions to drug treatment, and all other secondary measures, including those of high public health relevance. Both groups showed modest and similar reductions in drug use frequency over the first 3 months with no subsequent change, possibly suggesting a regression to the mean in both groups. Although our negative findings are consistent with prior studies in treatmentseeking patients in the United States, 5, 6, 8 they also may be a product of our participant characteristics as well as the ways in which the intervention was conducted and the outcomes were evaluated. Abstinence measure, which is used to assess one's goal for changing drug use (no goal, controlled use, occasional use, temporary abstinence, total abstinence slip is possible, total abstinence never use again). The reported "Goal of total abstinence from drugs" includes "Total abstinence, never use again" and "Total abstinence, slip is possible." First and most important, drug use in the sample was very heterogeneous, spanning casual marijuana use to severe opiate and stimulant abuse. Although the DAST-10 score, which measures severity and is strongly related to type of drug used, did not moderate intervention effects on frequency of drug use, it did moderate both treatment uptake and emergency department use in exploratory analyses of secondary outcomes. Participants in the brief intervention group with the most severe drug use problems, with a greater pattern of stimulant and opiate abuse, were more likely to pursue specialty treatment and had reduced use of the emergency department relative to those in the enhanced care as usual group. This is consistent with the 1 positive study of brief intervention for cocaine and opiate users by Bernstein et al, 7 although no effects were found on treatment uptake. In contrast, no benefit of the intervention was found for those in the lowest severity of drug use problems, predominantly marijuana users. Although legalization of marijuana use in Washington State did not occur until well after enrollment, the legalization climate may have served to normalize marijuana use, often not associated with work or personal problems, and reduce motivation for change for this substance. Second, the sample was severely socioeconomically disadvantaged. However, studies of alcohol brief intervention have not indicated that disadvantage/ poverty moderates brief intervention effect, 36 and the study by Bernstein et al drew participants from homeless and lowincome clinics. Third, the sample had a high rate of comorbid mental illness, which is known to be associated with poorer substance use outcomes. 37 These last 2 aspects of our population (poverty and mental illness), along with the fact that patients in this study received compensation, may limit the generalizability of our results. Other factors may have influenced the effectiveness of the brief intervention. First, the majority of participants had a single brief intervention contact, with only 47% receiving a follow-up booster call. Although more frequent contact may increase efficacy, 1 some studies have failed to show this. 38 Second, the participant's primary care physician did not deliver the intervention, nor did a research-confirmed expert. Although the current use of a physician-extender to deliver the intervention is consistent with extant integrated care models and has been shown effective in other contexts, 39 the physician might have more influence with a patient. 15 Third, despite efforts to simplify the assessment battery, all participants received up to 5 assessments, in which information about drug use was discussed, as well as DAST-10 feedback. It is possible that this may have inadvertently served to produce an intervention effect in the comparison group. 40 Fourth, measuring frequency but not quantity of drug use is a limited measure of outcome. Similarly, our measure of alcohol use did not include quantity consumed, limiting our ability to use alcohol as either a predictor or outcome variable. Currently there is no gold standard for quantifying problem drug use. Researchers measuring problem drug use outcomes must find a way to measure quantity, as well as frequency, of use. It is possible that our exploratory finding of reduced emergency department utilization could reflect changes in quantity but not frequency of drug use, although the finding may also be spurious. 
